# A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

> **NCT05305300** · PHASE1 · COMPLETED · sponsor: **Yisheng Biopharma (Singapore) Pte. Ltd.** · enrollment: 135 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A
- **BIOLOGICAL:** PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B

## Key facts

- **NCT ID:** NCT05305300
- **Lead sponsor:** Yisheng Biopharma (Singapore) Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-18
- **Primary completion:** 2022-05-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305300, "A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05305300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*